{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:29:52Z","timestamp":1770726592230,"version":"3.49.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0239686","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T18:08:14Z","timestamp":1601489294000},"page":"e0239686","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4020-5233","authenticated-orcid":true,"given":"Alexander S.","family":"Carlson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rigo I.","family":"Acevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-6567","authenticated-orcid":true,"given":"Roman","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9284-3608","authenticated-orcid":true,"given":"Agnes","family":"Gawne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra O.","family":"Sokolova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Bruce","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T.","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"pone.0239686.ref001","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fgene.2015.00157","article-title":"DNA repair mechanisms in cancer development and therapy","volume":"6","author":"A Torgovnick","year":"2015","journal-title":"Frontiers in genetics"},{"issue":"40","key":"pone.0239686.ref002","doi-asserted-by":"crossref","first-page":"e4975","DOI":"10.1097\/MD.0000000000004975","article-title":"Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis","volume":"95","author":"Z Baretta","year":"2016","journal-title":"Medicine"},{"issue":"14","key":"pone.0239686.ref003","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"E Castro","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0239686.ref004","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.","volume":"68","author":"E Castro","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"pone.0239686.ref005","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative Clinical Genomics of Advanced Prostate Cancer","volume":"162","author":"D Robinson","year":"2015","journal-title":"Cell"},{"issue":"5","key":"pone.0239686.ref006","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer","volume":"375","author":"CC Pritchard","year":"2016","journal-title":"The New England journal of medicine"},{"issue":"10","key":"pone.0239686.ref007","first-page":"785","article-title":"Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer.","volume":"15","author":"MT Schweizer","year":"2017","journal-title":"Clinical advances in hematology & oncology: H&O."},{"key":"pone.0239686.ref008","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"AD D'Andrea","year":"2018","journal-title":"DNA repair"},{"issue":"11","key":"pone.0239686.ref009","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.","volume":"5","author":"PA Konstantinopoulos","year":"2015","journal-title":"Cancer discovery"},{"issue":"12","key":"pone.0239686.ref010","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.2014.58.8848","article-title":"Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.","volume":"33","author":"CL Scott","year":"2015","journal-title":"J Clin Oncol"},{"issue":"18","key":"pone.0239686.ref011","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"J Mateo","year":"2015","journal-title":"The New England journal of medicine"},{"issue":"1","key":"pone.0239686.ref012","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.","volume":"21","author":"J Mateo","year":"2020","journal-title":"The Lancet Oncology."},{"key":"pone.0239686.ref013","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","author":"J de Bono","year":"2020","journal-title":"The New England journal of medicine"},{"issue":"4","key":"pone.0239686.ref014","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2019.02.002","article-title":"Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.","volume":"76","author":"CH Marshall","year":"2019","journal-title":"Eur Urol."},{"key":"pone.0239686.ref015","article-title":"Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study","author":"W Abida","year":"2020","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"pone.0239686.ref016","unstructured":"FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. U.S. Food and Drug Administration. 2020. Available from: https:\/\/www.fda.gov\/drugs\/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate"},{"key":"pone.0239686.ref017","unstructured":"FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. U.S. Food and Drug Administration. 2020. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer"},{"key":"pone.0239686.ref018","doi-asserted-by":"crossref","DOI":"10.4061\/2010\/201367","article-title":"Cellular responses to Cisplatin-induced DNA damage","volume":"2010","author":"A Basu","year":"2010","journal-title":"Journal of nucleic acids"},{"issue":"6","key":"pone.0239686.ref019","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2015.11.022","article-title":"Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.","volume":"69","author":"HH Cheng","year":"2016","journal-title":"Eur Urol"},{"issue":"18","key":"pone.0239686.ref020","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1002\/cncr.30808","article-title":"The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer","volume":"123","author":"MM Pomerantz","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"pone.0239686.ref021","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4103\/1008-682X.122593","article-title":"Chemotherapy and its evolving role in the management of advanced prostate cancer","volume":"16","author":"MT Schweizer","year":"2014","journal-title":"Asian journal of andrology"},{"issue":"10","key":"pone.0239686.ref022","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1200\/JCO.2017.75.7310","article-title":"Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.","volume":"36","author":"M Hussain","year":"2018","journal-title":"J Clin Oncol."},{"issue":"1","key":"pone.0239686.ref023","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2017.02.023","article-title":"Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.","volume":"72","author":"M Annala","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"pone.0239686.ref024","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.eururo.2018.01.010","article-title":"Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.","volume":"73","author":"J Mateo","year":"2018","journal-title":"Eur Urol"},{"issue":"5","key":"pone.0239686.ref025","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1464-410X.2011.10292.x","article-title":"Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer","volume":"109","author":"DJ Gallagher","year":"2012","journal-title":"BJU international"},{"issue":"12","key":"pone.0239686.ref026","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.","volume":"34","author":"HI Scher","year":"2016","journal-title":"J Clin Oncol."},{"issue":"10","key":"pone.0239686.ref027","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201846783","article-title":"Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness","volume":"19","author":"V Kari","year":"2018","journal-title":"EMBO reports"},{"issue":"12","key":"pone.0239686.ref028","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"DJ Khalaf","year":"2019","journal-title":"The Lancet Oncology"},{"issue":"1","key":"pone.0239686.ref029","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/s13104-016-2279-9","article-title":"Abiraterone acetate after progression with enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.","volume":"9","author":"Y Yamada","year":"2016","journal-title":"BMC research notes"},{"issue":"2","key":"pone.0239686.ref030","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/pcan.2014.53","article-title":"Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and\/or docetaxel","volume":"18","author":"HH Cheng","year":"2015","journal-title":"Prostate cancer and prostatic diseases"},{"issue":"2","key":"pone.0239686.ref031","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.eururo.2014.04.015","article-title":"Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.","volume":"68","author":"N Al Nakouzi","year":"2015","journal-title":"Eur Urol"},{"issue":"6","key":"pone.0239686.ref032","doi-asserted-by":"crossref","first-page":"E760","DOI":"10.1002\/ijc.29231","article-title":"CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel","volume":"136","author":"MD Wissing","year":"2015","journal-title":"International journal of cancer"},{"issue":"7","key":"pone.0239686.ref033","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1158\/1541-7786.MCR-09-0123","article-title":"PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.","volume":"7","author":"F Zhang","year":"2009","journal-title":"Molecular cancer research: MCR."},{"issue":"6","key":"pone.0239686.ref034","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.molcel.2006.05.022","article-title":"Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2","volume":"22","author":"B Xia","year":"2006","journal-title":"Molecular cell"},{"issue":"6","key":"pone.0239686.ref035","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.","volume":"37","author":"E Castro","year":"2019","journal-title":"J Clin Oncol"},{"key":"pone.0239686.ref036","article-title":"Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations.","volume":"3","author":"MT Schweizer","year":"2019","journal-title":"JCO precision oncology"},{"issue":"22","key":"pone.0239686.ref037","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1158\/1078-0432.CCR-17-0955","article-title":"MSH2 Loss in Primary Prostate Cancer.","volume":"23","author":"LB Guedes","year":"2017","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research."},{"issue":"4","key":"pone.0239686.ref038","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1172\/JCI132031","article-title":"Genomics of lethal prostate cancer at diagnosis and castration resistance","volume":"130","author":"J Mateo","year":"2020","journal-title":"The Journal of clinical investigation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0239686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T18:08:56Z","timestamp":1601489336000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0239686"}},"subtitle":[],"editor":[{"given":"Alvaro","family":"Galli","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0239686","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]}}}